Emyria (ASX:EMD)

Emyria (ASX:EMD)

A clinical stage biotech informed by patient experience. Tackling unmet needs in neuroscience & mental health #RealWorld

Founded 2018

Australia 11 employees Post-IPO Equity Total: $7.50M Health Care, Health and Wellness +1

Emyria (ASX:EMD) is a clinical stage biotech company founded in 2018 and headquartered in Australia. The company operates with the slogan "A clinical stage biotech informed by patient experience. Tackling unmet needs in neuroscience & mental health #RealWorld." Emyria Limited is focused on improving patient outcomes in neuroscience and mental health through a unique business model. The company's operations are divided into three main segments. Firstly, Emyria Clinics offer evidence-based and emerging therapies for mental health and other unmet needs across multiple sites. Secondly, Emyria Data provides robust and ethically-sourced Real-World Data gathered with patients, which is utilized to enhance Emyria’s distinct therapy and drug development programs. Lastly, Emyria Drug Discovery possesses one of the world's largest libraries of unique MDMA-like compounds developed in partnership with the University of Western Australia, along with a suite of high potency Ultra-Pure cannabinoids that are currently being evaluated in clinical trials for a range of mental health and select neuroscience indications. The company recently secured a $5.00MPost-IPO Equity investment on 22 November 2021 from Tattarang. Emyria's focus on utilizing real-world data to improve patient outcomes and its innovative drug discovery programs position it as a promising player in the healthcare and pharmaceutical industries.

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Equity	$2.50M	3	Tenmile, Taylor Collison Ltd +1	01 May 2023
Post IPO Equity	$5.00M	1	Tattarang	22 Nov 2021

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Equity

$2.50M

Tenmile, Taylor Collison Ltd +1

01 May 2023

Post IPO Equity

$5.00M

Tattarang

22 Nov 2021

FAQ About Emyria (ASX:EMD)

A clinical stage biotech informed by patient experience. Tackling unmet needs in neuroscience & mental health #RealWorld

Emyria (ASX:EMD) was founded in 2018.

Emyria (ASX:EMD) is headquartered in Australia.

Emyria (ASX:EMD) operates in Health Care, Health and Wellness and Pharmaceutical. Its work centres on biotech, neuroscience, mental health and patient experience.

Emyria (ASX:EMD) has approximately 11 employees.

Emyria (ASX:EMD) has completed 2 funding rounds, raising a total of $7.50M. The latest funding stage is Post-IPO Equity.

Top alternatives and competitors to Emyria (ASX:EMD) include Albert Labs, Gilgamesh Pharmaceuticals, Fabre-Kramer Pharmaceuticals, Inc., Cogniant, Clairvoyant Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Emyria (ASX:EMD) and Albert Labs are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Emyria (ASX:EMD)

Funding Rounds & Investors (2)

Emyria (ASX:EMD) Alternatives & Competitors

FAQ About Emyria (ASX:EMD)